497 related articles for article (PubMed ID: 18611066)
1. B-cell-targeted therapy for systemic lupus erythematosus: an update.
Ding C; Foote S; Jones G
BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
[TBL] [Abstract][Full Text] [Related]
2. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
3. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
4. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
5. B-cell targeted treatments for lupus: the journey counts as much as the destination.
Falgarone G; Dhote R; Boissier MC
Joint Bone Spine; 2012 Oct; 79(5):437-40. PubMed ID: 22480746
[TBL] [Abstract][Full Text] [Related]
6. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Stohl W; Hiepe F; Latinis KM; Thomas M; Scheinberg MA; Clarke A; Aranow C; Wellborne FR; Abud-Mendoza C; Hough DR; Pineda L; Migone TS; Zhong ZJ; Freimuth WW; Chatham WW; ;
Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
[TBL] [Abstract][Full Text] [Related]
7. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.
Looney RJ
Drugs; 2010 Mar; 70(5):529-40. PubMed ID: 20297867
[TBL] [Abstract][Full Text] [Related]
8. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
Hui-Yuen JS; Nguyen SC; Askanase AD
Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
[TBL] [Abstract][Full Text] [Related]
9. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
10. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
Tanaka Y
J UOEH; 2011 Jun; 33(2):173-81. PubMed ID: 21702122
[TBL] [Abstract][Full Text] [Related]
11. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Espinosa G; Cervera R
Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
[TBL] [Abstract][Full Text] [Related]
12. SLE - Rituximab in lupus.
Eisenberg R
Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844
[TBL] [Abstract][Full Text] [Related]
13. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series.
Gualtierotti R; Borghi MO; Gerosa M; Schioppo T; Larghi P; Geginat J; Meroni PL
Clin Exp Rheumatol; 2018; 36(4):643-647. PubMed ID: 29533753
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
15. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
16. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
Eisenberg R; Albert D
Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in the treatment of systemic lupus erythematosus.
Robak E; Robak T
Curr Drug Targets; 2009 Jan; 10(1):26-37. PubMed ID: 19149533
[TBL] [Abstract][Full Text] [Related]
18. Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.
Fattah Z; Isenberg DA
Expert Opin Biol Ther; 2014 Mar; 14(3):311-26. PubMed ID: 24387632
[TBL] [Abstract][Full Text] [Related]
19. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
Bela MM; Espinosa G; Cervera R
Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
[No Abstract] [Full Text] [Related]
20. [What's new in internal medicine: emerging treatments for systemic lupus erythematosus].
Hachulla É
Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S241-4. PubMed ID: 22202645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
